Education
About Us
Working with TipRanks
Follow Us
Theranexus SA (DE:3VG)
:3VG
3VG Stock Chart & Stats
€2.74
-€0.06(-8.12%)
At close: 4:00 PM EST
€2.74
-€0.06(-8.12%)
Day’s Range― - ―
52-Week Range€0.35 - €3.25
Previous CloseN/A
Volume0.00
Average Volume (3M)549.00
Market Cap
€29.17M
Enterprise ValueN/A
Total Cash (Recent Filing)€966.59K
Total Debt (Recent Filing)€2.87M
Price to Earnings (P/E)―
Beta-0.06
Next Earnings
May 05, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.14
Shares Outstanding13,796,556
10 Day Avg. Volume140
30 Day Avg. Volume549
Financial Highlights & Ratios
PEG Ratio0.04
Price to Book (P/B)-2.98
Price to Sales (P/S)2.16
P/FCF Ratio-1.45
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Theranexus SA News
3VG FAQ
What was Theranexus SA’s price range in the past 12 months?
Theranexus SA lowest stock price was €0.35 and its highest was €3.25 in the past 12 months.
What is Theranexus SA’s market cap?
Theranexus SA’s market cap is €29.17M.
When is Theranexus SA’s upcoming earnings report date?
Theranexus SA’s upcoming earnings report date is May 05, 2026 which is in 138 days.
How were Theranexus SA’s earnings last quarter?
Theranexus SA released its earnings results on Sep 25, 2025. The company reported -€0.138 earnings per share for the quarter, missing the consensus estimate of N/A by -€0.138.
Is Theranexus SA overvalued?
According to Wall Street analysts Theranexus SA’s price is currently Overvalued.
Does Theranexus SA pay dividends?
Theranexus SA does not currently pay dividends.
What is Theranexus SA’s EPS estimate?
Theranexus SA’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Theranexus SA have?
Theranexus SA has 13,796,556 shares outstanding.
What happened to Theranexus SA’s price movement after its last earnings report?
Theranexus SA reported an EPS of -€0.138 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -6.167%.
Which hedge fund is a major shareholder of Theranexus SA?
Currently, no hedge funds are holding shares in DE:3VG
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Theranexus SA
Theranexus société anonyme, a biopharmaceutical company, develops drug candidates for the treatment of central nervous system disorders. The company's lead drug candidate is THN102, which is in Phase II clinical trial to treat sleep/wake disorders. It also develops THN201 for the treatment of neurocognitive disorders linked to Alzheimer's disease; and THN101 to treat neuropathic pain. The company was founded in 2013 and is based in Lyon, France.